Drug intelligence / Profile preview

HKP107

Development stage: Preclinical
Lead developer: Hankook Korus Pharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HKP107 is a biosimilar monoclonal antibody candidate being developed by Hankook Korus Pharm. It is designed to target the Programmed Cell Death Protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), HKP107 aims to restore and enhance anti-tumor T-cell activity. The drug is a biosimilar of nivolumab (Opdivo) and is currently in the preclinical stage, specifically in process development, for the treatment of various cancers.

Other names: nivolumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on HKP107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HKP107.

Explore the full profile